Clarithromycin and Lomitapide interaction

Clarithromycin and Lomitapide: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Clarithromycin label · effective 2026-01-01

Major

Lomitapide, lovastatin, and simvastatin ( 4.5 )

Contraindicationsnames LomitapideView label on DailyMed
Major

Lomitapide, Lovastatin, and Simvastatin Concomitant administration of clarithromycin tablets with lomitapide is contraindicated due to potential for markedly increased transaminases [see Warnings and Precautions ( 5.4 ) and Drug Interactions ( 7 )].

Contraindicationsnames LomitapideView label on DailyMed
Major

These include colchicine toxicity with colchicine; markedly increased transaminases with lomitapide; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia and cardiac arrhythmias (e.g., torsades de pointes) with disopyramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine,…

Warnings and precautionsnames LomitapideView label on DailyMed
Major

The use of clarithromycin with lomitapide, simvastatin, lovastatin, ergotamine, or dihydroergotamine is contraindicated [see Contraindications ( 4.5 , 4.6 ) and Drug Interactions ( 7 )].

Warnings and precautionsnames LomitapideView label on DailyMed
Major

Lomitapide: Concomitant use of clarithromycin with lomitapide is contraindicated [see Contraindications ( 4.5 )].

Warnings and precautionsnames LomitapideView label on DailyMed

From the Lomitapide (Juxtapid) label · effective 2026-01-20

Major

Concomitant administration of JUXTAPID with moderate or strong CYP3A4 inhibitors, as this can increase JUXTAPID exposure [see Warnings and Precautions (5.6) , Drug Interactions (7.1) , and Clinical Pharmacology (12.3) ].

Contraindicationsby drug classView label on DailyMed
Major

Concomitant use with strong or moderate CYP3A4 inhibitors ( 4 ).

Contraindicationsby drug classView label on DailyMed
Major

Concomitant use of moderate or strong CYP3A4 inhibitors with JUXTAPID is contraindicated [see Drug Interactions (7.1) ].

Warnings and precautionsby drug classView label on DailyMed
Major

If treatment with moderate or strong CYP3A4 inhibitors is unavoidable, JUXTAPID should be stopped during the course of treatment.

Warnings and precautionsby drug classView label on DailyMed
Major

Strong and moderate CYP3A4 inhibitors are contraindicated with JUXTAPID.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.